LY6G6D and malignant colon neoplasm: A recent study evaluated LY6G6D and CD15 as predictive biomarkers for the response to JAK- and MAPK-directed therapies and found that these two biomarkers promote chemo-immune-resistance in immunologically compromised colon cancers and can be used as biomarkers to decide patients treatments (Giordano et al., 2019).